A. Li

701 total citations
13 papers, 149 citations indexed

About

A. Li is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, A. Li has authored 13 papers receiving a total of 149 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 2 papers in Physiology. Recurrent topics in A. Li's work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (3 papers). A. Li is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Diagnosis and Treatment (3 papers). A. Li collaborates with scholars based in United States, France and Germany. A. Li's co-authors include David R. Spigel, Leora Horn, Mahfuzah Mohamed, Félix Couture, George P. Keogh, Glenwood Goss, Edward B. Garon, Lawrence H. Einhorn, Ben Creelan and Maen Hussein and has published in prestigious journals such as Annals of Oncology, Journal of Thoracic Oncology and Journal of Asthma.

In The Last Decade

A. Li

12 papers receiving 148 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Li United States 6 142 101 29 13 12 13 149
Nivedita Aanur United States 5 149 1.0× 108 1.1× 23 0.8× 13 1.0× 24 2.0× 6 164
E. Felip Font Spain 6 89 0.6× 77 0.8× 20 0.7× 9 0.7× 8 0.7× 15 109
Dae Ho Lee South Korea 4 171 1.2× 110 1.1× 33 1.1× 13 1.0× 16 1.3× 6 182
Miranda Gogishvili United States 7 109 0.8× 89 0.9× 22 0.8× 14 1.1× 5 0.4× 22 127
J. Remon Masip France 5 108 0.8× 95 0.9× 15 0.5× 11 0.8× 12 1.0× 23 135
Y. Bautista Mexico 5 120 0.8× 136 1.3× 23 0.8× 12 0.9× 5 0.4× 6 181
Kathi Seidl-Rathkopf United States 3 88 0.6× 48 0.5× 11 0.4× 6 0.5× 9 0.8× 6 112
N. Girard France 4 81 0.6× 73 0.7× 19 0.7× 15 1.2× 13 1.1× 24 110
Karim Amrane France 5 105 0.7× 70 0.7× 26 0.9× 11 0.8× 10 0.8× 18 133
Tamta Makharadze United States 6 71 0.5× 56 0.6× 20 0.7× 9 0.7× 4 0.3× 16 108

Countries citing papers authored by A. Li

Since Specialization
Citations

This map shows the geographic impact of A. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Li more than expected).

Fields of papers citing papers by A. Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Li. The network helps show where A. Li may publish in the future.

Co-authorship network of co-authors of A. Li

This figure shows the co-authorship network connecting the top 25 collaborators of A. Li. A scholar is included among the top collaborators of A. Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Li. A. Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Hu, Xuhui, Dapeng Chen, Jian Dai, et al.. (2025). HANDSON Hand: Strategies and Approaches for Competitive Success at CYBATHLON 2024. Bioengineering. 12(3). 228–228. 1 indexed citations
2.
Zhang, Xinyue, et al.. (2024). Neuroticism and asthma: Mendelian randomization analysis reveals causal link with mood swings and BMI mediation. Journal of Asthma. 62(4). 674–683. 1 indexed citations
3.
4.
John, Thomas, Hiroshi Sakai, Satoshi Ikeda, et al.. (2020). 1311P First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA. Annals of Oncology. 31. S847–S848. 8 indexed citations
5.
Brahmer, Julie R., T-E. Ciuleanu, Michael Schenker, et al.. (2020). 67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1. Annals of Oncology. 31. S1444–S1445. 3 indexed citations
6.
7.
Brahmer, Julie R., Leora Horn, Suresh S. Ramalingam, et al.. (2019). O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response. Journal of Thoracic Oncology. 14(11). S1152–S1153. 6 indexed citations
8.
Antonia, Scott, Scott Gettinger, Hossein Borghaei, et al.. (2018). P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012. Journal of Thoracic Oncology. 13(10). S458–S458. 3 indexed citations
9.
Font, E. Felip, Scott Gettinger, Scott Antonia, et al.. (2017). Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v462–v462. 22 indexed citations
10.
Spigel, David R., Maen Hussein, David Waterhouse, et al.. (2017). Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v461–v461. 76 indexed citations
11.
Barlési, Fabrice, Martin Steins, Leora Horn, et al.. (2016). Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. Annals of Oncology. 27. vi420–vi420. 16 indexed citations
12.
Felip, Enriqueta, Jan P. van Meerbeeck, Jennifer Moriatis Wolf, et al.. (2016). 193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment. Journal of Thoracic Oncology. 11(4). S141–S141. 3 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nivedita Aanur Breakdown of academic impact, for papers by E. Felip Font Breakdown of academic impact, for papers by Dae Ho Lee Breakdown of academic impact, for papers by Miranda Gogishvili Breakdown of academic impact, for papers by J. Remon Masip Breakdown of academic impact, for papers by Y. Bautista Breakdown of academic impact, for papers by Kathi Seidl-Rathkopf Breakdown of academic impact, for papers by N. Girard Breakdown of academic impact, for papers by Karim Amrane Breakdown of academic impact, for papers by Tamta Makharadze
Rankless by CCL
2026